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503Abstracts
esomeprazole (EAC) results in direct medical cost savings
compared with 1-week triple therapy (OAC) followed 
by three weeks omeprazole monotherapy, while offering
comparable effectiveness.
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ASSOCIATED WITH MINOR NON-STEROIDAL
ANTI-INFLAMMATORY DRUGS (NSAID)
RELATED GASTRO-INTESTINAL (GI) EVENTS
Annemans L1,Vanoverbeke N2
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OBJECTIVES: In the assessment of NSAID related GI
events, many authors focus on severe events leading to
hospitalisation. This study aimed at describing medical
practice, resource utilisation and costs of different GI
events related to chronic NSAID use in osteo-arthritis
(OA) and rheumatoid arthritis (RA) patients in Belgium.
METHODS: A random sample of 231 OA and RA
patients with GI events associated with NSAID use was
included in a multicenter GP level chart review. Charts
were assessed by the GP and monitored by an indepen-
dent researcher for all medical resource use related to the
event. Direct medical costs were calculated by multiply-
ing resource use with standard costs for the health insur-
ance. GI events were categorised as GI discomfort (=
minor event), symptomatic ulcer, anaemia with occult
bleeding and severe (i.e. hospitalised) gastro-intestinal
pathologies. RESULTS: Thirty-ﬁve patients (15.2%) were
RA patients, 196 (84.8%) OA. The average age of the
sample was 61.0y (st.dev 14.7y). 45% were male. The
median duration of a GI event was 10 days, the average
was 23 days. The average cost per patient was €284. The
cost per type of event (in €) was as follows (p < 0.001
Kruskal Wallis): GI Discomfort (n = 155): 198 (SE = 41);
Ulcer (n = 66): 364 (SE = 28); Anaemia (n = 7): 756 (SE
= 234); Severe GI (n = 3): 1,896 (SE = 1,585). Total cost
(n x mean) was: GI Discomfort: 30,657 (46.7%); Ulcer:
24,020 (36.6%); Anaemia: 5,293 (8.1%); Severe GI:
5,688 (8.7%). It was thus shown that GI discomfort, due
to the relative high number of patients, leads to 47% of
total GI related costs. CONCLUSIONS: Many patients
with minor NSAID related GI events visit a physician.
The resulting use of healthcare resources to manage these
events should be taken into account in economic evalua-
tions of measures to prevent GI events.
GASTROINTESTINAL DISEASES/DISORDERS—
Clinical Outcomes
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META-ANALYSIS OF ESOMEPRAZOLE 40MG
AND LANSOPRAZOLE 30MG IN THE HEALING
OF REFLUX OESOPHAGITIS
Edwards S
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OBJECTIVE: Two studies have reported results compar-
ing esomeprazole 40mg and lansoprazole 30mg in the
healing of reﬂux oesophagitis. The two studies come to
different conclusions. One study shows superiority for
esomeprazole at four and eight weeks while the other
claims equivalence. The aim of this work was to combine
the results of the 2 studies by meta-analysis to ascertain
if there is a difference in healing rates with esomeprazole
40mg and lansoprazole 30mg. METHODS: Meta-
analysis of intention-to-treat (ITT) endoscopic healing
rates at four and eight weeks. If the healing rates were
not presented in an ITT format they were recalculated.
ITT was deﬁned as “patients being analysed in the treat-
ment arm that they entered at randomisation, regardless
of whether they dropped-out, received the incorrect
treatment or withdrew before completion of the trial”.
RESULTS: At 4 weeks, esomeprazole 40mg is signiﬁ-
cantly more effective than lansoprazole 30mg in the
healing of reﬂux oesophagitis (Relative Risk 1.05; 95%
CI 1.02–1.09). Similarly, at 8 weeks esomeprazole 40mg
is signiﬁcantly more effective than lansoprazole 30mg
(Relative Risk 1.04; 95% CI 1.01–1.06). A chi-squared
test was carried out to investigate possible heterogeneity.
Signiﬁcant heterogeneity was not detected at four or eight
weeks. CONCLUSIONS: Esomeprazole 40mg is signiﬁ-
cantly more effective than lansoprazole 30mg in the
healing of reﬂux oesophagitis at 4 and 8 weeks.
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OBJECTIVE: To analyze the safety, effectiveness and cost
savings of rabeprazole at the McGuire Veterans Affairs
Medical Center. Similar effectiveness and safety pro-
ﬁles among the proton pump inhibitors (PPI) prompted 
a dose-per-dose interchange (1 :1) of rabeprazole with 
currently prescribed PPIs (lansoprazole and omeprazole)
when rabeprazole was added to the VA National Formu-
lary priced 75%–80% less than its competitors. Rabepra-
zole was also identiﬁed as drug-of-choice for future use
in PPI-naïve patients. METHODS: Patients with active
rabeprazole prescriptions (N = 3885) and those failing
therapy (N = 249) as of 5/22/02 were selected for analy-
sis (total N = 4134). Patients were divided into two
subsets: those participating in the PPI therapeutic inter-
change: N = 2088; and PPI-naïve patients prescribed
rabeprazole after formulary addition: N = 1797. A retro-
spective database analysis of 14,565 PPI prescriptions
from January 1, 2000–May 22, 2002 was conducted to
assess PPI prescribing trends, pharmacy acquisition costs,
tolerance, effectiveness and dose creep for these individ-
uals. RESULTS: Safety: Patients experience an adverse
drug event (ADE): N = 65 (1.6%). Effectiveness: Patients
failing rabeprazole: N = 184 (4.5%). Total number 
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discontinuing rabeprazole for effectiveness or ADE; N =
249 (6%). Estimated annual PPI acquisition costs were
reduced 50%, avoiding over 1/2 million dollars (US) in
pharmacy acquisition costs despite a 32% increase in
units dispense. Final cost analysis will include the effect
of dose-creep in rabeprazole patients and associated clinic
costs. CONCLUSION: Rabeprazole appears safe, effec-
tive, and cost-saving as indicated by the low number 
of patients discontinuing rabeprazole for either clinical
failure or intolerance. Cost savings were signiﬁcant but
offset by a predictable and substantial increase in use.
*Data available 10-months post interchange; 1-year data
will be presented at meeting.
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OBJECTIVES: If multiple diagnostic modalities are avail-
able, an insurmountable number of strategies have to be
compared to determine the most efﬁcient one. Our aim is
to develop a multistage decision analytic model to decide
upon the most cost-effective diagnostic strategy to guide
the treatment of faecal incontinence by physiotherapy and
surgical anal sphincter repair. METHODS: Incremental
cost-effectiveness analysis of diagnostic strategies, each
including one to seven diagnostic modalities, ﬁve of which
consist of two or three subtests. The primary endpoint is
the success of physiotherapy or, in case of failure, the
success of subsequent operative anal sphincter repair. 
An informed choice was made for a restricted set of
strategies eligible for economic evaluation and modelling,
based on methodological papers and on expert opinion
on patient logistics. RESULTS: In theory, 8,41E + 13 
possible decisions have to be evaluated for each therapy.
This number can be reduced to 1,063,859, if the most 
cost-effective subtest combination within each diagnostic
modality is determined beforehand. This is very likely the
most informative combination, for the cost differences are
minimal. Next, four modalities make up an inseparable
diagnostic test array from the patients’ logistics point of
view. Within this array individual tests may be omitted
and the order of tests is redundant. The array further
reduces the number of decisions to be evaluated to 777.
CONCLUSIONS: The number of possible diagnostic
strategies can be succesfully reduced to manageable pro-
portions through an evaluation of subtest combinations
ﬁrst and by taking into account patients’ logistics.
GASTROINTESTINAL DISEASES/DISORDERS—
Quality of Life/Utility/Preference/Productivity
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OBJECTIVE: Compare the Health Related Quality of
Life (HRQoL) and Psychological Well-being (PW) of 
IBS and non-IBS patients (controls) and evaluate the 
perceived stress of IBS patients’ relatives. METHODS:
Observational, prospective study including a sample of
455 IBS patients meeting Rome II criteria, 69 controls,
and 195 IBS patients’ relatives. The controls were selected
from those subjects who had attended a health centre
with a relative due to digestive problems (excluding IBS).
All samples were selected from the consulting rooms of
86 Spanish gastroenterologists and physicians. In order
to measure HRQoL and PW patients and controls 
completed the EQ-5D and Psycological Well-Being 
Index (PGWBI). Patients’ relatives completed an adapted
version of the Levenstein’s Perceived Stress Question-
naire’ (LPSQ). RESULTS: The mean (SD) age of patients
was 43(14) years and 76.5% were female. There were 
no statistical signiﬁcant differences in age and gender
between patients and controls. 67.9% of patients pre-
sented some concomitant disease, while in controls the
percentage was lower (39.1%) (p < 0.01). Patients pre-
sented worse HRQoL than controls, presenting a higher
presence of problems in all EQ-5D dimensions (p < 0.05),
except self-care. 76.5 and 54.7% of patients declared
having pain and anxiety problems, respectively, compared
to 15.9 and 20.3% of controls. In terms of PGWBI,
patients presented more problems than controls in all
dimensions (p < 0.05) except ‘alimentation’ and ‘sexual
relations’. Relatives obtained a mean (SD) LPSQ score 
of 0.54 (0.12) on a scale from 0 to 1 (maximum stress).
Relatives of patients with a higher IBS severity (rated by
patients and doctors) showed a higher stress level than
those relatives of less severe patients. CONCLUSIONS:
Patients with IBS showed a signiﬁcant deterioration in
HRQoL, in almost all HRQoL dimensions, compared
with non-IBS subjects. Relatives showed varying levels of
stress according to the patient’s IBS severity, stress being
higher in relatives of more severe patients.
